NRGene Technologies Statistics

Total Valuation

NRGene Technologies has a market cap or net worth of ILS 32.13 million. The enterprise value is 26.10 million.

Market Cap	32.13M
Enterprise Value	26.10M

Important Dates

The next estimated earnings date is Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

NRGene Technologies has 12.99 million shares outstanding. The number of shares has increased by 0.36% in one year.

Current Share Class	n/a
Shares Outstanding	12.99M
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	35.48%
Owned by Institutions (%)	4.72%
Float	7.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.30
PB Ratio	1.55
P/TBV Ratio	3.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.51
EV / Sales	4.45
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.63

Financial Position

The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.25.

Current Ratio	1.69
Quick Ratio	1.60
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	-0.32
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -60.53% and return on invested capital (ROIC) is -28.67%.

Return on Equity (ROE)	-60.53%
Return on Assets (ROA)	-22.61%
Return on Capital (ROIC)	-28.67%
Revenue Per Employee	117,170
Profits Per Employee	-344,507
Employee Count	50
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +28.54% in the last 52 weeks. The beta is -0.29, so NRGene Technologies's price volatility has been lower than the market average.

Beta (5Y)	-0.29
52-Week Price Change	+28.54%
50-Day Moving Average	319.93
200-Day Moving Average	361.79
Relative Strength Index (RSI)	20.18
Average Volume (20 Days)	15,550

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NRGene Technologies had revenue of ILS 5.86 million and -17.23 million in losses. Loss per share was -1.40.

Revenue	5.86M
Gross Profit	2.64M
Operating Income	-15.07M
Pretax Income	-17.26M
Net Income	-17.23M
EBITDA	-14.16M
EBIT	-15.07M
Loss Per Share	-1.40

Full Income Statement

Balance Sheet

The company has 11.33 million in cash and 5.09 million in debt, giving a net cash position of 6.24 million or 0.48 per share.

Cash & Cash Equivalents	11.33M
Total Debt	5.09M
Net Cash	6.24M
Net Cash Per Share	0.48
Equity (Book Value)	20.27M
Book Value Per Share	1.60
Working Capital	6.31M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.38 million and capital expenditures -625,007, giving a free cash flow of -16.01 million.

Operating Cash Flow	-15.38M
Capital Expenditures	-625,007
Free Cash Flow	-16.01M
FCF Per Share	-1.23

Full Cash Flow Statement

Margins

Gross margin is 45.12%, with operating and profit margins of -257.26% and -294.02%.

Gross Margin	45.12%
Operating Margin	-257.26%
Pretax Margin	-294.60%
Profit Margin	-294.02%
EBITDA Margin	-241.77%
EBIT Margin	-257.26%
FCF Margin	n/a

Dividends & Yields

NRGene Technologies does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.36%
Shareholder Yield	-0.36%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NRGene Technologies has an Altman Z-Score of -7.75. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.75
Piotroski F-Score	n/a